How fast can I increase retatrutide dose?

Standard research protocol: escalate every 4 weeks if previous dose was tolerated. If GI side effects emerge, hold at current dose 4 more weeks before increasing. Jastreboff 2023 used 4-week increments from 0.5mg up to 12mg.

What is the minimum effective dose?

Jastreboff 2023 saw measurable weight changes at 1 mg/week (~9% at 48 weeks). Below 0.5 mg the effect is minimal — useful as a tolerability starter, not as a maintenance dose.

Should I hold dose if side effects persist?

Yes. If nausea, vomiting, or chest tightness persist beyond 2 weeks at any dose, hold or reduce. Increasing through unresolved side effects compounds them and risks discontinuation.

Retatrutide Titration Schedule: Complete 6-Month Escalation Guide for UAE Researchers (2026)

Published 23 June 2026 · REVIVE Peptides Research Desk · 10 min read

TL;DR. The Jastreboff 2023 NEJM protocol escalates retatrutide every 4 weeks from 0.5 mg to a maintenance dose of 4, 8, or 12 mg weekly SC. Each step requires confirmation that the previous dose was tolerated. The single biggest research mistake is escalating through unresolved nausea — it compounds and forces discontinuation.

The Foundation Protocol — Jastreboff 2023

Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Phase 2 (Jastreboff 2023, NEJM) tested four dose targets: 1, 4, 8, and 12 mg weekly. Each arm titrated from a starting dose with 4-week increments. Weight loss at 48 weeks scaled with the dose: 8.7% at 1 mg, 17.5% at 4 mg, 22.8% at 8 mg, 24.2% at 12 mg.

Standard 24-Week Titration Schedule

Week	Dose	What to expect
1–4	0.5 mg weekly SC	Mild GI possible; system adapting
5–8	1 mg weekly SC	GI symptoms peak then plateau
9–12	2 mg weekly SC	Appetite suppression evident
13–16	4 mg weekly SC	Decision point for maintenance vs continue
17–20	8 mg weekly SC	Deeper effect; HR rise mild
21–24	12 mg weekly SC	Maximum studied dose
25+	Maintain at chosen dose	Continue indefinitely per protocol

The Three Maintenance Dose Targets

4 mg weekly — Conservative

~17.5% weight loss at 48 weeks (Jastreboff 2023)
Lower side-effect burden
Slower descent, more sustainable for long-term research
Best for: longer time horizon, tolerability priority

8 mg weekly — Standard

~22.8% weight loss at 48 weeks
Moderate side-effect burden, manageable
Best for: standard research protocols, balanced approach

12 mg weekly — Maximum

~24.2% weight loss at 48 weeks (curve still descending)
Highest side-effect burden including 6–8 bpm HR elevation
Best for: maximal effect research, shorter time horizon

Vial Math For Each Step

REVIVE supplies retatrutide as 5 mg and 10 mg vials. Reconstitution math depends on your dose and BAC water volume — see our retatrutide reconstitution math guide. Quick reference using a 10 mg vial + 2 mL BAC water (5 mg/mL):

Dose	Draw volume (1mL syringe)	IU equivalent
0.5 mg	0.10 mL	10 IU
1 mg	0.20 mL	20 IU
2 mg	0.40 mL	40 IU
4 mg	0.80 mL	80 IU
8 mg	1.60 mL (two injections of 0.80 mL)	2 x 80 IU
12 mg	Use a 2 mL/200 IU syringe or split across days	240 IU

For doses above 4 mg, consider reconstituting with less BAC water for a more concentrated solution — e.g., 10 mg + 1 mL BAC water = 10 mg/mL, halving draw volume.

When to Slow or Hold the Schedule

Persistent nausea beyond 2 weeks at current dose. Hold; do not escalate.
Vomiting more than once per week. Reduce by one step.
Resting heart rate jumps over 15 bpm above baseline. Hold; consult monitoring data.
Severe abdominal pain. Stop immediately. Rule out pancreatitis with medical supervision.
Gallbladder symptoms (RUQ pain after fatty meals). Hold; investigate.

Tolerability Tips That Actually Work

Inject same day each week. Consistency reduces side-effect variability.
Inject in evening — sleep through peak nausea window.
Reduce dietary fat for first 48 hours post-injection. Slows gastric emptying, but a low-fat meal limits the worst of it.
Increase fluid + electrolytes. Slowed GI motility loses water; constipation is a major secondary effect.
Ginger and small frequent meals. Same logic that works for chemotherapy nausea applies here.

Deeper dive: GLP-1 nausea mitigation guide.

UAE-Specific Considerations

Refrigerate reconstituted vials immediately. UAE summer heat exposure shortens the 28-day shelf life — see storage guide.
Plan around Ramadan if relevant. Fasting research subjects need timing adjustments to avoid hypoglycaemia overlap.
Heat acclimation matters. GLP-1s can blunt thirst signalling; outdoor heat exposure during UAE summers increases dehydration risk.

Starting a retatrutide research protocol in the UAE?
REVIVE supplies retatrutide 5 mg and 10 mg vials with HPLC certificates, cold-chain delivery, and reconstitution support.
View retatrutide vials →

Research use only. Retatrutide supplied by REVIVE is labelled and sold strictly for in-vitro and research purposes — not for human consumption.

References

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526.
Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(9):1234–1247.
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529–544.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311–319.